US 11,833,144 B2
Treating autoimmune disease
John A. Copland, III, Ponte Vedra Beach, FL (US); and Hu Zeng, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Aug. 24, 2021, as Appl. No. 17/410,137.
Claims priority of provisional application 63/070,505, filed on Aug. 26, 2020.
Prior Publication US 2022/0062259 A1, Mar. 3, 2022
Int. Cl. A61K 31/4545 (2006.01); A61P 37/06 (2006.01); A61K 31/496 (2006.01)
CPC A61K 31/4545 (2013.01) [A61K 31/496 (2013.01); A61P 37/06 (2018.01)] 18 Claims
 
1. A method for treating a mammal having an autoimmune disease, wherein said method comprises administering a SCD1 polypeptide inhibitor to said mammal, wherein said SCD1 polypeptide inhibitor is a compound having Formula (II):

OG Complex Work Unit Chemistry
or pharmaceutically acceptable salt thereof;
wherein:
R1 is halo;
X is —(C═O)NR4—,
Y is

OG Complex Work Unit Chemistry
 and
R2, R3, and R4 are each independently H or an unsubstituted C1-6alkyl.